Drugs Not ‘On Radar’ For Medicare Coverage Review, Official Says
This article was originally published in RPM Report
Executive Summary
The director of Medicare’s coverage and analysis group says that, at the moment, no biopharma products are being considered for a national coverage determination. Another official says Medicare cannot use comparative effectiveness data in making reimbursement decisions.
You may also be interested in...
CMS Coverage Group Changes Management, But Not Priorities
Director of CMS’ Coverage and Analysis Group Louis Jacques will leave the agency in March; his replacement, Deputy Tamara Syrek Jensen, will continue to make Coverage with Evidence Development a top priority.
CMS Proposed National Coverage Decision Topic List Exempts Biopharma
The Centers for Medicare & Medicaid Services’ new list of “potential” topics for National Coverage Decisions includes 33 separate ideas, most proposed by the public. Not one is directly related to a biopharma topic. CMS’ coverage team swears it remains interested in drug-related coverage issues—but still, this is one list it is nice not to be on.
Medicare Will Cover Provenge Labeled Uses, CMS Proposes; Off-Label Is Up To Contractors
Agency decides against requiring coverage with evidence development for off-label uses.